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Abstract
G protein-coupled receptors (GPCRs) remain the primary conduit by which cells detect 
environmental stimuli and communicate with each other1. Upon activation by extracellular 
agonists, these seven transmembrane domain (7TM)-containing receptors interact with 
heterotrimeric G proteins to regulate downstream second messenger and/or protein kinase 
cascades1. Crystallographic evidence from a prototypic GPCR, the β2-adrenergic receptor (β2AR), 
in complex with its cognate G protein, Gs, has provided a model for how agonist binding promotes 
conformational changes that propagate through the GPCR and into the nucleotide binding pocket 
of the G protein α-subunit to catalyze GDP release, the key step required for GTP binding and 
activation of G proteins2. The structure also offers hints on how G protein binding may, in turn, 
allosterically influence ligand binding. Here we provide functional evidence that G protein 
coupling to β2AR stabilizes a ‘closed’ receptor conformation characterized by restricted access to 
and egress from the hormone binding site. Surprisingly, the effects of G protein on the hormone 
binding site can be observed in the absence of a bound agonist, where G protein coupling driven 
by basal receptor activity impedes the association of agonists, partial agonists, antagonists and 
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inverse agonists. The ability of bound ligands to dissociate from the receptor is also hindered, 
providing a structural explanation for the G protein-mediated enhancement of agonist affinity, 
which has been observed for many GPCR-G protein pairs. Our studies also suggest that in contrast 
to agonist binding alone, coupling of a G protein in the absence of an agonist stabilizes large 
structural changes in a GPCR. The effects of nucleotide-free G protein on ligand binding kinetics 
are shared by other members of the superfamily of GPCRs, suggesting that a common mechanism 
may underlie G protein-mediated enhancement of agonist affinity.
Keywords
GPCR; nucleotide-free; receptor conformation
Sequencing of the human genome revealed the magnitude of the GPCR superfamily, 
identifying over 800 genes encoding GPCRs, making this class of receptors the third-largest 
gene family3. Despite the varying nature of the chemical stimuli, which range from photons 
to small-molecule odorants and hormones to larger peptides and proteins, the generation of 
G protein-mediated signals proceeds by a common mechanism. Following activation, the 
receptor engages a heterotrimeric G protein and catalyzes release of GDP from the G protein 
α-subunit (Gα). Intracellular GTP then binds the nucleotide-free G protein, allowing it to 
regulate downstream effectors (adenylyl cyclase, phospholipase C, ion channels, etc.) to 
elicit cellular responses4. We recently used x-ray crystallography2, hydrogen-deuterium 
exchange mass spectrometry5, and electron microscopy6 to characterize an agonist-GPCR-G 
protein ternary complex in the absence of nucleotide. These studies revealed dramatic 
conformational changes in G that are stabilized by binding to agonist-activated receptor and 
provided insight into the mechanism by which GPCRs bind G proteins to promote 
nucleotide exchange. Here, we suggest an explanation for the allosteric communication 
which links the nucleotide binding site on the G protein to the hormone binding site on the 
receptor, with a focus on conformational changes in the extracellular face of the receptor that 
alter access to the hormone binding site.
GPCR-G protein interactions have historically been monitored using radioligand binding 
assays. Observations as early as the 1970s suggested that G protein coupling enhances 
agonist affinity for the receptor, and can be abolished by uncoupling the G protein from the 
receptor with guanine nucleotides7. These and other data formed the basis for the ternary 
complex model of agonist-receptor-G protein interactions8,9. In this paradigm, the active 
state of the receptor is stabilized by both the agonist and G protein, and enhancement of 
agonist affinity arises due to the positive cooperativity between agonist and G protein. 
However, using purified β2AR•Gs complexes, we observed peculiar binding characteristics 
of the antagonist [3H]dihydroalprenolol ([3H]DHAP) to β2AR (Fig. 1a). As illustrated, 
addition of GDP increases the observed binding of a saturating concentration of [3H]DHAP, 
whereas removal of GDP using a nucleotide lyase, apyrase, decreases [3H]DHAP binding. 
The apyrase-mediated decrease in [3H]DHAP binding is reversed upon addition of excess 
GDP, suggesting that the decrease is indeed due to the formation of nucleotide-free 
β2AR•Gs complexes. Removal of GDP from the β2AR•Gs complex relies on the constitutive 
activity of β2AR and the rapid hydrolysis (by apyrase) of GDP released from the α-subunit 
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of Gs, Gsα. The nucleotide-free status of Gsα in these β2AR•Gs complexes was confirmed 
by rapid [35S]GTPγS binding kinetics (Extended Data Figure 1)10. The observed deficit in 
[3H]DHAP binding to nucleotide-free β2AR•Gs is the result of slower [3H]DHAP 
association (Fig. 1b, Extended Data Figure 2). GDP enhances [3H]DHAP association in a 
concentration-dependent manner, with similar effects achieved by complete β2AR•Gs 
uncoupling with GTPγS. Although nucleotides do not significantly affect the affinity (Kd) of 
[3H]DHAP, their modulatory capacity is gamma phosphate-dependent since GTPγS is ∼10-
fold more potent than GDP (Extended Data Figure 3). Thus, β2AR bound to nucleotide-free 
G protein adopts a conformation characterized by restricted access to the hormone binding 
site.
Crystallographic and pharmacological evidence suggests that the active conformation of 
β2AR is stabilized by nucleotide-free Gs or by a single-chain camelid antibody raised 
against agonist-bound β2AR (nanobody Nb80) (Fig. 2a)2,11,12. As illustrated in Fig. 2b (and 
Extended Data Figure 4a), Nb80 stabilizes a conformation of β2AR that restricts [3H]DHAP 
association, similar to nucleotide-free Gs. Importantly, Nb80 also slows the association of 
full agonist, [3H]formoterol (Fig. 2c), as well aspartial agonist, [3H]CGP-12177 (Fig. 2d). 
These data suggest that in the nucleotide-free Gs- or Nb80-stabilized active state, the β2AR 
adopts a ‘closed’ conformation impairing access to the orthosteric binding site, regardless of 
the orthosteric ligand's cooperativity with G protein. These data agree with our previous 
observation that the inverse agonist ICI-118,551 blocks the formation of β2AR•Gs 
complexes, but is unable to disrupt pre-formed complexes10. Nb80 also impairs binding of 
inverse agonist [3H]carvedilol to β2AR by modestly decreasing the observed association rate 
(Fig. 2e) but significantly decreasing total binding, suggesting that Nb80 and [3H]carvedilol 
do not simultaneously occupy β2AR.
Agonist-promoted G protein engagement and subsequent nucleotide loss would be expected 
to stabilize the active, closed receptor conformation, thus trapping the agonist in the 
orthosteric site and enhancing its observed affinity. Indeed, uncoupling G protein from 
receptor using the GTP analog GppNHp has been shown to accelerate agonist dissociation 
from β2AR13. Such agonist-G protein cooperativity is not predicted for neutral antagonists 
like alprenolol, which do not stimulate G protein coupling and thus should not stabilize the 
closed conformation. However, we have previously demonstrated that Gs can be ‘forced’ to 
form a complex with β2AR bound to antagonist alprenolol10, provided that free nucleotide is 
removed, indicating that antagonist-bound β2AR retains enough basal activity to engage Gs. 
Consistent with this model, Figures 2f and Extended Data Figure 4b clearly illustrate a 
progressive slowing of [3H]DHAP (or [3H]CGP-12177, data not shown) dissociation in 
response to increasing Nb80 concentrations, suggesting that Nb80-mediated stabilization of 
the closed, active receptor conformation can trap [3H]DHAP in the orthosteric binding site.
Analysis of access to the hormone binding sites in inactive- and active-state β2AR structures 
provides a structural rationale for the slowing of agonist and antagonist association (Figs. 3, 
Extended Data Figure 6 and Supplementary Video 1). The binding of Gs or Nb80 to β2AR 
stabilizes a rearrangement of the cytoplasmic end of TM7 (Fig. 4a & b) immediately above 
the ligand binding site and a change in the structure of the extracellular loop between TM4 
and TM5 (ECL2). In comparison to the inactive β2AR, the structure of the β2AR-Gs or -
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Nb80 (or related Nb6B914) complex identifies two aromatic residues, Phe193(5.25 or ECL2) 
and Tyr3087.35, that move approximately 2-2.5 Å closer to each other to form a lid-like 
structure over the orthosteric binding site. Lys3057.32 also contributes to capping the 
orthosteric site by trading its salt bridge15 with Asp192ECL2 for an interaction with the 
backbone carbonyl of Phe193ECL2 (Fig. 4c). These structural changes are stabilized in the 
active forms of β2AR bound to either the ultra-high affinity agonist BI-167107 or the 
smaller, low affinity agonist adrenaline15, and formation of this ‘lid’ would be expected to 
sterically obstruct both ligand association and dissociation.
To validate this structural model, we tested whether a residue smaller than tyrosine could 
modify the capacity of Nb80 to slow ligand association. Mutation of Tyr3087.35 to alanine, 
previously shown to lower agonist affinity for β2AR16, significantly diminishes the capacity 
of Nb80 to slow the association of [3H]DHAP and even the agonist [3H]formoterol 
(Extended Data Figure 5), as suggested by recent molecular dynamics simulations17. 
Interestingly and in contrast to [3H]DHAP association, preincubation with 10 μM Nb80 also 
enhances the extent of [3H]formoterol binding in the Y308A mutant. Eliminating barriers 
that impairs access to the orthosteric site (eg. Y308A) allows the agonist to at least enter the 
receptor where it can stabilize nanobody binding. The enhancement, therefore, is a reflection 
of the capacity of the agonist [3H]formoterol to cooperatively stabilize Nb80 binding and 
vice-versa and concomitantly slow the dissociation of the bound agonist (Extended Data 
Figure 5d). The data also suggest that while Tyr3087.35 significantly limits access to the 
orthosteric site, other residues may work in concert with Tyr3087.35 in the active β2AR 
conformation to slow agonist dissociation.
It is noteworthy that the movement of Phe193ECL2 and Tyr3087.35 is not fully observed in 
the crystal structure of β2AR bound to an agonist alone18, nor in the inactive-state structure 
of β1AR bound to the agonist isoprenaline19 (Extended Data Figure 6, Supplementary Video 
1, and Supplementary Video 2). Binding of G protein or G protein-mimetic (nanobody) is 
sufficient to stabilize the closed, active conformation since their effects on ligand binding 
kinetics (as in Figs. 1 and 2) are agonist-independent. An agonist may enhance G protein 
engagement but poorly stabilizes the closed, active conformation by itself. Additionally, the 
data presented here suggest that formation of the closed, active conformation stabilized by 
the nucleotide-free G protein can occur due to basal receptor activity, in keeping with 
predictions of more recent models of GPCR pharmacology such as the extended and cubic 
ternary complex models20,21 (see supplemental materials for extended discussion). 
Moreover, conformational changes stabilized by the nucleotide-free G protein influence not 
only agonist binding, but ligand binding in general, implying that the role of nucleotides 
needs to be included in an updated version of ternary complex model.
The capacity of G proteins to stabilize a closed receptor conformation explains the poorly 
defined GTPγS-mediated increase in radiolabeled antagonist binding observed with several 
GPCRs, including muscarinic, α-adrenergic, adenosine, and opioid receptors22–25 (as in 
Extended Data Figure 7 & Extended Data Figure 8). We analyzed the behavior of the M2 
muscarinic acetylcholine receptor (M2R) and the μ-opioid receptor (MOPr) to determine 
whether GTPγS-mediated uncoupling relieves a G protein-stabilized closed conformation. 
We focused on these receptors since structural models are available for both inactive and 
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active conformations26-29, and to determine whether the mechanism we propose for β2AR is 
shared among other GPCRs. The active-state structure of the M2R, in particular, revealed 
similar conformational changes to the β2AR in that a ‘lid-like’ structure is formed above the 
orthosteric site27 (see Supplementary Video 4 & Supplementary Video 5). Although the 
structural changes are not identical, the effect of G proteins (or nanobodies) on the 
association and dissociation of ligands at the orthosteric sites is shared among β2AR, M2R, 
and MOPr (Extended Data Figure 9 and Supplementary Video 3), suggesting that the 
allosteric effects of G proteins on orthosteric agonists may be manifested by conceptually 
common mechanisms. More discussion of the details and implications are described in the 
supplementary materials. Additionally, many recent studies have focused on the allosteric 
effect of sodium ions on Class A GPCR ligand binding and signaling30. Outward movement 
of TM6 during receptor activation collapses the sodium binding pocket in many Class A 
GPCRs, thus it appears that loss of bound sodium is necessary for G proteins to stabilize a 
closed, active receptor conformation.
The formation of the closed conformation also has particular significance to the 
development of allosteric modulators targeting Class A GPCRs. Most allosteric modulator 
binding sites have focused on the extracellular vestibule located above the orthosteric 
binding sites. For the muscarinic M2R for example, the potent allosteric positive modulator 
LY2119620 utilizes residues that form the ‘lid’ in the active, closed conformation as 
described here, as the floor of the vestibule27. Stabilization of this closed conformation may 
therefore be an important aspect on the differentiation between positive allosteric 
modulators, which enhance agonist binding and activation, and negative allosteric 
modulators, which decrease agonist binding.
In summary, we provide pharmacological and biochemical evidence suggesting that the 
closed, active conformation of GPCRs is stabilized by the nucleotide-free G protein, 
allowing G proteins to influence passage of ligands to the orthosteric binding site. The 
dramatic effect of G proteins on either ligand association or dissociation is consistent with, 
and in fact validates, structural models generated from x-ray crystallography where G 
protein coupling on the intracellular face of the receptor allosterically influences the 
structure of the extracellular face. Agonist or hormone binding enhances G protein 
engagement, where by formation of the active receptor conformation is accompanied by 
nucleotide loss from the G protein. Therefore, the capacity of G proteins to enhance agonist 
binding affinity is structurally and energetically linked to the agonist's capacity to promote 
nucleotide loss from Gα.
Methods
Large-scale Purification of β2AR
β2AR bearing an N-terminal FLAG tag and C-terminal 10×-His tag was expressed in Sf9 
cells (Invitrogen) and purified as previously described2.
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Expression and purification of G protein and Nanobodies
Gs and Go heterotrimer were expressed in HighFive™ (Invitrogen) insect cells using 
recombinant baculovirus and purified by chromatography on Ni-NTA, MonoQ, and 
Superdex 200 resin, as previously described31. Nanobodies were expressed in Escherichia 
coli and purified as previously described11,14,27.
Membrane Preparations
HEK293T cells (ATCC) were used for small-scale expression and purification of β2AR and 
mutants. Cells were grown in DMEM + 10% FBS to ∼70% confluency, then transfected 
with mYFP-β2AR (pCMV5, 6 μg DNA per 10-cm plate) using Lipofectamine 2000. Cells 
were harvested 40-48 hrs post-transfection in ice-cold lysis buffer buffer (50 mM HEPES, 
pH 8.0, 65 mM NaCl, 1 mM EDTA, 35 μg/ml phenylmethylsulfonyl fluoride, 32 μg/ml each 
tosyl-L-phenylalanine-chloromethylketone and tosyl-L-lysine-chloromethylketone, 3.2 
μg/ml leupeptin, 3.2 μg/ml ovomucoid trypsin inhibitor). The cell suspension was sonicated 
using a Branson Sonifier and centrifuged for 20 minutes at 25,000g. The pellet was 
resuspended in wash buffer (50 mM HEPES, pH 8.0, 100 mM NaCl with protease inhibitors 
listed above) using a Dounce homogenizer, then centrifuged for 20 minutes at 25,000g. The 
pellet was resuspended and homogenized in minimal wash buffer and the volume was 
adjusted to reach a final protein concentration of 5 mg/ml as measured by the Bradford 
protein assay. Membranes were frozen by slowly pouring into liquid nitrogen and stored at 
-80 °C until use.
Enrichment of β2AR and β2AR-Y308A from HEK293T cells
Frozen membranes were thawed on ice and NaCl, MgCl2, and GTPγS were added to reach 
final concentrations of 300 mM, 1 mM, and 10 μM, respectively. Timolol was then added to 
a final concentration of 1 μM and the membranes were incubated for 10 minutes on ice. 
Receptors were solubilized for 1 hour at 4 °C in the presence of 1% dodecylmaltoside 
(DDM) and 0.1% cholesterol hemisuccinate (CHS). Following centrifugation for 30 minutes 
at 25,000g, the supernatant was applied to Ni-NTA agarose. The column was slowly washed 
with 20 column volumes of 20 mM HEPES, pH 8.0, 300 mM NaCl, 0.1% DDM, 0.01% 
CHS to remove bound timolol. Receptor was eluted in the same buffer plus 200 mM 
imidazole and concentrated using an Amicon 30 kDa-cutoff spin concentrator for addition to 
the rHDL reconstitution mixture.
Receptor Reconstitution into rHDL Particles
Reconstitutions were performed as described32, with the amount of receptor added never 
exceeding 20% of the total reaction volume. For samples that contained Gs, the purified 
heterotrimer was added to the pre-formed β2AR-rHDL particles, incubated for 2 hours at 
4°C, and BioBeads (Bio-Rad) were used to remove the added detergent. Nucleotide-free 
Gs•β2AR complex was prepared by incubating β2AR-Gs-rHDL particles with apyrase in the 
presence of 1 mM MgCl2 for 30 minutes at room temperature, or alternately, 2 hours at 4°C. 
If needed, the sample was passed through a Superdex 200 gel filtration column to remove 
free nucleotide and apyrase.
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Radioligand Association Experiments using rHDL Particles
All assays were performed in Tris-buffered saline (TBS; 25 mM Tris-HCl, pH 7.4, 136 mM 
NaCl, 2.7 mM KCl) with a final concentration of 0.05% w/v bovine serum albumin. 
Reaction components were mixed and pre-incubated at room temperature (see below) before 
the addition of radioligand to initiate the association time course. Aliquots were withdrawn 
at the indicated times and filtered over Whatman GF/B filters pre-soaked in 0.3% w/v 
polyethyleneimine. Filters were washed with ice-cold TBS, dried, and subjected to liquid 
scintillation counting on a TopCount™ NXT (Perkin-Elmer, MA). Bound ligand never 
exceeded 10% of the total ligand added.
Kinetic binding experiments with [3H]DHAP and Nb80, β2AR-rHDL—For 
association experiments, receptor in rHDL was pre-incubated with varying concentrations of 
Nb80 and the reaction was started by addition of 5 nM [3H]DHAP (Perkin Elmer). For 
dissociation experiments, the samples were first incubated with 5 nM [3H]DHAP for 30 
minutes, followed by incubated with varying Nb80 concentrations for 30 minutes. The 
reaction was started by adding 50 μM cold alprenolol. Non-specific binding was determined 
in the presence of 10 μM (+/-)-propranolol.
Binding experiments with [3H]DHAP and Gs•β2AR nucleotide-free complexes
—For association experiments, gel-filtered samples of apyrase-treated Gs•β2AR-rHDL 
particles were incubated with 5 nM [3H]DHAP to bind any receptor that was not complexed 
with Gs. The experiment was started by adding varying amounts of either GDP or GTPγS. 
For “equilibrium” binding experiments, samples were incubated with all the indicated 
components at room temperature for 90 minutes before filtration. Non-specific binding was 
determined in the presence of 10 μM (+/-)-propranolol.
[3H]Formoterol Association to β2AR—β2AR-rHDL was incubated with the indicated 
concentrations of Nb80 for 30 minutes at room temperature. [3H]formoterol (Perkin Elmer) 
was added to reach 10 nM final concentration. These assays also contained 1 mM ascorbic 
acid in the reaction buffer. Non-specific binding was determined in the presence of 10 μM 
(+/-)-propranolol.
[3H](-)-CGP-12177 Association to β2AR—β2AR-rHDL was incubated with the 
indicated concentrations of Nb80 for 30 minutes at room temperature. [3H](-)-CGP-12177 
(Perkin Elmer) was added to reach 1 nM final concentration. Non-specific binding was 
determined in the presence of 10 μM (+/-)-propranolol.
[3H]Carvedilol Association to β2AR—Due to high amounts of non-specific 
[3H]carvedilol (American Radiolabeled Chemicals) binding both to bovine serum albumin 
(BSA) and to the glass fiber filters typically used for separation, β2AR-rHDL was diluted 
into empty rHDL particles rather than into a 5× BSA solution (0.25% w/v BSA in TBS 
buffer) prior to addition to the assay mix. Using empty rHDL in place of BSA was critical 
for maintaining sample recovery from the assay plate while improving the signal-to-noise 
ratio of the assay. The receptor was incubated with the indicated concentrations of Nb80 for 
15 minutes at room temperature, then for 30 minutes at 4°C. [3H]carvedilol was added to 
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reach 1 nM final concentration. Aliquots were withdrawn at the indicated time points and 
bound ligand was isolated using gel filtration on Sephadex G75 resin. Non-specific binding 
was determined in the presence of 10 μM (+/-)-propranolol.
Extended Data
Extended Data Figure 1. Confirmation of nucleotide removal from β2AR•Gs by apyrase
Gs and Flag-tagged β2AR were reconstituted in rHDL and treated with the non-specific 
nucleotide lyase, apyrase. Samples were applied to an anti-Flag affinity resin to remove 
products of the GDP degradation (GMP and Pi). Samples were incubated with 100 nM 
[35S]GTPγS at room temperature. At various times, samples were subjected to rapid 
filtration through glass fiber filters (GF/B) followed by 10 volumes of ice-cold buffer washes 
containing 10 μM GDP. Filters were dried and subjected to liquid scintillation counting 
(Top-Count™, Perkin-Elmer). To a first approximation the rapid binding event suggests that 
the complex is empty of nucleotide, based on the limited temporal resolution of this mixing 
and filtration technique. [3H]DHAP and [35S]GTPγS binding to the reconstituted complex 
yields a final R:G ratio of 1:0.95, suggesting that up to 95% of the β2AR-rHDL particles 
contain a single functional G protein. This suggest that only those G proteins associated with 
the β2AR will bind [35S]GTPγS within this time frame in the absence of receptor agonists. 
Data are shown as mean ± SEM from n=3 independent experiments performed in duplicate.
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Extended Data Figure 2. GDP accelerates [3H]DHAP binding to β2AR•Gs
a) Time course monitoring [3H]DHAP association to apyrase-treated β2AR•Gs complexes in 
the presence of varying GDP concentrations. GDP increases both the observed association 
rate constant and the maximum binding of [3H]DHAP. b) Concentration-response showing 
enhancement of the observed [3H]DHAP association rate constant by GDP (EC50 = 181 
± 66 nM). All data are shown as mean ± SEM from n=3 independent experiments performed 
in duplicate.
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Extended Data Figure 3. Effect of guanine nucleotides on [3H]DHAP binding to β2AR•Gs
a) In saturation binding assays, addition of GTPγS to apyrase-treated β2AR•Gs complexes 
increased the observed Bmax for [3H]DHAP without significantly altering Kd (Control: Bmax 
= 5.5 ± 0.52 fmol, Kd = 0.88 nM; +GTPγS: Bmax = 16.6 ± 1.9 fmol, Kd = 0.56 nM) b) Both 
GDP and GTPγS could enhance maximal [3H]DHAP binding in a concentration-dependent 
manner (GDP Log(EC50) = -6.42 ± 0.12, or EC50 ∼386 nM; GTPγS Log(EC50) = -7.45 ± 
-0.16, or EC50 ∼35 nM). All data are shown as mean ± SEM from n=3 independent 
experiments performed in duplicate.
DeVree et al. Page 10
Nature. Author manuscript; available in PMC 2017 November 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Extended Data Figure 4. Effect of Nb80 on antagonist binding to β2AR
a) Association of [3H]DHAP is progressively slowed following pre-incubation of β2AR with 
increasing concentrations of Nb80. b) If [3H]DHAP is allowed to first equilibrate with 
β2AR, Nb80 slows [3H]DHAP dissociation from β2AR in a concentration-dependent 
manner. c) Due to the dramatic slowing of [3H]DHAP binding kinetics, Nb80 (but not a 
control nanobody, Nb30, which has no effect on agonist affinity for β2AR) appears 
competitive with [3H]DHAP if insufficient time is given to reach equilibrium. Data shown 
are from assays incubated 90 minutes at room temperature. All data are shown as mean ± 
SEM from n=3 independent experiments performed in duplicate.
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Extended Data Figure 5. Y308A mutation abolishes the rate-slowing effects of Nb80
a) and b) Time course of [3H]DHAP binding to wild-type β2AR (a) or β2AR-Y308A (b) 
following pre-incubation of receptor with Nb80. Nb80 significantly slowed [3H]DHAP 
association to wild-type β2AR (-Nb80 kobs = 0.45 ± 0.05 min-1 or t½ = 1.5 ± 0.2 min, 
+Nb80 kobs = 0.20 ± 0.03 min-1 or t½ = 3.5 ± 0.5 min; p = 0.011 by an unpaired two-tailed 
t-test), but less effectively slowed [3H]DHAP association to β2AR-Y308A (-Nb80 kobs = 
0.50 ± 0.06 min-1 or t½ = 1.4 ± 0.2 min; +Nb80 kobs = 0.32 ± 0.01 min-1 or t½ = 2.2 ± 0.1 
min; p = 0.05 by an unpaired two-tailed t-test. All data are shown as mean ± SEM from n=4 
(-Nb80) or n=3 (+Nb80) independent experiments performed in duplicate. c) and d) Time 
course of [3H]formoterol binding to wild-type β2AR (c) or β2AR-Y308A (d) following pre-
incubation of receptor with Nb80. Nb80 slowed [3H]formoterol association to wild-type 
β2AR (0.1 μM Nb80 kobs = 0.68 ± 0.13 min-1 or t½ = 1.0 ± 0.2 min, 10 μM Nb80 kobs = 
0.27 ± 0.05 min-1 or t½ = 2.6 ± 0.5 min; p = 0.031 by an unpaired two-tailed t-test). 
However, with β2AR-Y308A, Nb80 had little effect on the observed association rate 
constant but enhanced the amount of [3H]formoterol bound (0.1 μM Nb80 kobs = 0.37 ± 0.11 
min-1 or t½ = 1.9 ± 0.6 min with a plateau of 10.1 ± 0.8 fmol, 10 μM Nb80 kobs = 0.53 
± 0.13 min-1 or t½ = 1.3 ± 0.4 min with a plateau of 21.3 ± 1.2 fmol; unpaired two-tailed t-
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test of the kobs values showed p = 0.4). All data are shown as mean ± SEM from n=4 
independent experiments performed in duplicate.
Extended Data Figure 6. The closed conformation stabilized by agonist and G protein (or mimic)
Illustrated are the crystal structures of agonist- vs. inverse agonist-bound of the β2AR (cyan) 
and β1AR (yellow), where only β2AR is bound to G protein. Similarly, the μ-opioid receptor 
(MOPr, orange) adopts a closed conformation upon binding G protein surrogate, Nb39. 
(β2AR; PDB 2RH1, β2AR•Gs; PDB 3SN6, β1AR; PDB 2YCW, β1AR-iso; PDB 2Y03, 
MOPr; PDB 4DKL, MOPr-Nb39; PDB 5C1M, M2R; PDB 3UON, M2R-Nb9-8; PDB 
4MQS).
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Extended Data Figure 7. Effect of guanine nucleotides on [3H]antagonist binding are also seen in 
competition binding assays
a) Agonist (isoproterenol) competition binding using apyrase-treated β2AR•Gs complexes 
shows the characteristic G protein-dependent shift in agonist affinity, along with a dramatic 
increase in total [3H]DHAP binding, upon the addition of 10 μM GTPγS. b) Normalization 
of the data from a) yields a plot representative of what is commonly reported in the 
literature. c) Similar to β2AR, agonist (morphine) competition binding using MOPr•Go 
complexes shows the characteristic G protein-dependent shift in agonist affinity, along with 
a dramatic increase in total [3H]DPN binding, upon the addition of 10 μM GTPγS. d) 
Normalization of the data from c). All data are shown as mean ± SEM from n=3 
independent experiments performed in duplicate.
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Extended Data Figure 8. Mu opioid receptor and M2 muscarinic acetylcholine receptor behave 
similarly to β2AR when bound to nucleotide-free G protein or an active-state stabilizing 
nanobody
a) Following apyrase treatment of M2R•Go complexes, addition of 10 μM GTPγS enhances 
association of [3H]N-methylscopolamine ([3H]NMS) to M2R (Vehicle kobs = 0.32 ± 0.02 
min-1 or t½ = 2.2 ± 0.1 min, +GTPγS kobs = 0.54 ± 0.02 min-1 or t½ = 1.3 ± 0.1 min; p = 
0.002 by an unpaired two-tailed t-test). Data are shown as mean ± SEM from n=3 
independent experiments performed in duplicate. Addition of GDP was also able to increase 
the rate of [3H]NMS binding (inset; pEC50 = 6.91 ± 0.18 or EC50 ∼123 nM; mean ± SEM 
from n=2 independent experiments performed in duplicate). b) Pre-treatment of M2R with 
either 10 μM (black circles) or 100 μM (red squares) Nb9-827 impairs association of 
[3H]iperoxo to M2R (10 μM Nb9-8 kobs = 0.68 ± 0.09 min-1 or t½ = 1.0 ± 0.2 min, 100 μM 
Nb9-8 kobs = 0.25 ± 0.04 min-1 or t½ = 2.8 ± 0.5 min; p = 0.04 by an unpaired two-tailed t-
test). Data are shown as mean ± SEM from n=3 (10 μM Nb9-8) or n=2 (100 μM Nb9-8) 
independent experiments performed in duplicate. c) Addition of 10 μM GTPγS to apyrase-
treated MOPr•Go complexes hastened association of the antagonist [3H]diprenorphine 
([3H]DPN) to MOPr (Apyrase kobs = 0.06 ± 0.02 min-1 or t½ = 9.8 ± 1.3 min, +GTPγS kobs 
= 0.12 ± 0.01 min-1 or t½ = 5.6 ± 0.6 min; p = 0.1 by an unpaired two-tailed t-test). The 
effect of nucleotide-free G protein was recapitulated by pre-incubating MOPr with Nb3928 
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(inset; control kobs = 0.13± 0.01 min-1, +100 μM Nb39 kobs = 0.07 ± 0.02 min-1). Data are 
shown as mean ± SEM from n=2 (MOPr•Go) or n=3 (MOPr + Nb39) independent 
experiments performed in duplicate.
Extended Data Figure 9. The extracellular regions in the active conformations of peptide 
hormone/agonist receptors MOPr and NTS-R1
Illustrated are the crystal structures of the inactive and active (or partially active NTS-R1) 
conformations of the MOPr and NTS-R1 from the top or extracellular view of the receptor. 
The surface rendering highlights residues or structure on the extracellular face that change 
upon receptor activation (circled). The mu-opioid receptor (MOPr) in its inactive 
conformation (purple) is compared to the Nb39-bound (G protein mimic) form in blue. 
Similarly, the inactive NTS-R133 (green) is compared with a mutant NTS-R134 that adopts a 
partially active conformation (orange). (MOPr; PDB 4DKL, MOPr-Nb39; PDB 5C1M, 
NTS-R1; PDB 4GRV and active-like NTS-R1; PDB 4XEE).
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Extended Data Figure 10. Model of G protein-dependent high-affinity agonist binding
As in Figure 5 (of the main text), nucleotide-free G protein-stabilized family A GPCRs 
experience alterations in the extracellular face of the receptor, thus affecting orthosteric 
binding site. In a monoamine receptor like the β2AR, G protein binding and GDP loss 
accompanies the stabilization of a closed, active conformation of the receptor, as in a). b) 
For family members such as MOPr or NTS-R1, where the peptide hormones/agonists are 
considerably larger, the influence of the G protein-mediated changes in the extracellular 
domain structure result in similar effects on orthosteric ligand dissociation. Rather than 
closing over the orthosteric site as with monoamine receptors as in a) the extracellular face 
may contain structures and residues that ‘pinch’ the larger ligands.
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Figure 1. Guanine nucleotides influence antagonist binding to β2AR•Gs complexes
a) Binding of 2 nM [3H]DHAP to β2AR•Gs in the absence or presence of GDP. Addition of 
apyrase to GDP-bound β2AR•Gs led to a progressive decrease in [3H]DHAP binding over 
time, which could be restored with excess GDP. b) Addition of increasing concentrations of 
GDP enhances the rate and extent of [3H]DHAP binding to apyrase-treated β2AR•Gs 
complexes. Data in a) are shown as mean ± SEM from n=3 independent experiments 
performed in duplicate. Data in b) are representative of three independent experiments.
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Figure 2. Trapping active-state β2AR with Nb80 slows both antagonist and agonist association
a) Nb80 (red) mimics G protein (yellow) in both its binding site and the β2AR conformation 
it stabilizes. The structure of Nb80-bound β2AR (3p0g) is shown in orange, Gs-bound β2AR 
(3sn6) in cyan. b) Pre-incubation of β2AR with increasing concentrations of Nb80 
progressively slows association of neutral antagonist [3H]DHAP to β2AR. c) Nb80 also 
slows association of full agonist [3H]formoterol, d) partial agonist [3H]CGP12177, and e) 
inverse agonist [3H]carvedilol to β2AR. f) Nb80 stabilizes the closed, active conformation 
and slows [3H]DHAP dissociation from β2AR in a concentration-dependent manner. Data in 
b) and f) are representative of three independent experiments. All other data are specific 
binding, shown as mean ± SEM from n=3 independent experiments performed in duplicate.
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Figure 3. Activation of β2AR closes the hormone binding site
a) Stabilization of the β2AR active conformation by Gs (or Nb80) brings the side chains of 
Phe193ECL2 and Tyr3087.35 closer to one another compared to their positions in structures in 
the absence of G protein. b) Closer view of the orthosteric site, highlighting Phe193ECL2 and 
Tyr3087.35. Distances (in Ångstroms) between the hydroxyl on Tyr3087.35 and 2-carbon on 
the phenyl ring of Phe193ECL2 are indicated. c) and d) A surface view comparing the 
extracellular face of β2AR in inactive (panel c) or active (panel d) conformations, showing 
how G protein-stabilized structural rearrangements occlude the hormone binding site in the 
active state. e) and f) Cutaway view illustrating closure of the hormone binding site around 
the bound agonist in the active state. The inverse agonist carazolol is shown in orange, the 
agonist BI-167107 is shown in yellow.
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Figure 4. Allosteric communication between β2AR G protein- and hormone-binding sites
a) In the β2AR active state (cyan), the cytoplasmic end of TM6 moves away from the 
receptor core by ∼14 Å relative to its position in the inactive-state structure, allowing for an 
inward movement of TM7. b) Rotation of TM7 allows Tyr3267.53 (of the highly conserved 
NPxxY motif) to fill the space vacated by the conserved aliphatic residue Ile2786.40. c) The 
rotation of TM7 repositions Tyr3087.35 and Lys3057.32. This conformational change allows 
Lys3057.32 to coordinate the backbone carbonyl of Phe193ECL2, stabilizing its movement 
toward Tyr3087.35 to form a “lid” over the hormone binding site.
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Figure 5. Basis for G protein-dependent high-affinity agonist binding
Agonist binding promotes the receptor-G protein interaction and GDP release from Gα. In 
this nucleotide-free state, the C-terminal helix of Gα remains embedded in the receptor core, 
stabilizing the conformational changes at both the intracellular and extracellular faces of the 
receptor. At the extracellular side, the orthosteric binding site closes around the bound 
agonist, sterically opposing agonist dissociation and thereby enhancing the observed affinity. 
Constitutive (basal) receptor activity may also activate the G protein, releasing GDP and 
thereby stabilizing the ‘closed’ conformation of the receptor in the absence of an agonist. 
See also Extended Data Figure 10.
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